CoChat
Sign Up
Cited by 269Parkinson's Disease Mechanisms and TreatmentsDeep Brain Stimulation and Movement DisordersNeurotransmitter Receptor Influence on Behavior

The DOI matches its Crossref record, with a small difference in title or year; 168 of the 171 references it cites were found in a registry or an index.

Dopamine Dysregulation Syndrome: An Overview of its Epidemiology, Mechanisms and Management

OʼSullivan, Sean S., Evans, Andrew H., Lees, Andrew J.·2009·CNS Drugs
DOI 10.2165/00023210-200923020-00005
Open this paper in CoChat — free account

Abstract

Dopamine dysregulation syndrome (DDS) is a relatively recently described iatrogenic disturbance that may complicate long-term symptomatic therapy of Parkinson's disease. Patients with DDS develop an addictive pattern of dopamine replacement therapy (DRT) use, administering doses in excess of those required to control their motor symptoms. The prevalence of DDS in patients attending specialist Parkinson's disease centres is 3-4%. Amongst the behavioural disturbances associated with DDS are punding, which is a complex stereotyped behaviour, and impulse control disorders (ICDs), such as pathological gambling, hypersexuality, compulsive shopping and compulsive eating. We review the risk factors and potential mechanisms for the development of DDS, including personality traits, potential genetic influences and Parkinson's disease-related cognitive deficits. Impulsive personality traits are prominent in patients developing DDS, and have been previously associated with the development of substance dependence. Candidate genes affecting the dopamine 'D(2)-like' receptor family have been associated with impulsive personality traits in addition to drug and nondrug addictions. Impaired decision making is implicated in addictive behaviours, and decision-making abilities can be influenced by dopaminergic medications. In Parkinson's disease, disruption of the reciprocal loops between the striatum and structures in the prefrontal cortex following dopamine depletion may predispose to DDS. The role of DRT in DDS is discussed, with particular reference to models of addiction, suggesting that compulsive drug use is due to progressive neuroadaptations in dopamine projections to the accumbens-related circuitry. Evidence for neuroadaptations and sensitization occurring in DDS include enhanced levodopa-induced ventral striatal dopamine release. Levodopa is still considered the most potent trigger for DDS in Parkinson's disease, but subcutaneous apomorphine and oral dopamine agonists may also be responsible. In the management of DDS, further research is needed to identify at-risk groups, thereby facilitating more effective early intervention. Therefore, an increased awareness of the syndrome amongst treating physicians is vital. Medication reduction strategies are employed, particularly with regard to avoiding rapidly acting 'booster' DRT formulations. Psychosocial treatments, including cognitive-behavioural therapy, have been beneficial in treating substance use disorders and ICDs in non-Parkinson's disease patients, but there are currently no published trials of psychological interventions in DDS. Further studies are also required to identify factors that can predict those patients with DDS or ICDs who will derive benefit from surgical interventions such as deep brain stimulation.

Overview

Integrity signals

Registry

Crossref · 10.2165/00023210-200923020-00005

Cites

168 of 168 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 6

  1. Rylander, 1972, Psychiatr Neurol Neurochir, 75, 203
  2. McElroy, 1994, J Clin Psychiatry, 55, 242
  3. Molina, 2000, Mov Disord, 15, 869, 10.1002/1531-8257(200009)15:5<869::AID-MDS1016>3.0.CO;2-I · DOI
  4. Poewe, 1990, Adv Neurol, 53, 339
  5. OʼSullivan, 2007, Mov Disord, 22, S163
  6. Smeding, 2007 May, J Neurol Neurosurg Psychiatry, 78 (5), 517

Cited by

Sorted by citations

See all 269

Related

See all

Metadata

Authors
OʼSullivan, S. S., Evans, A. H., & Lees, A. J.
Affiliations
  • The Royal Melbourne Hospital (AU)
  • University College London (GB)
ORCID
Venue
CNS Drugs
Publisher
Springer Science and Business Media LLC
Published
2009
Volume
23
Issue
2
Pages
157-170
ISSN
1172-7047 (ISSN-L)
DOI
10.2165/00023210-200923020-00005
OpenAlex
W2130441789
Cited by
265
References
171
Citations by year
2026: 11 · 2025: 10 · 2024: 18 · 2023: 10 · 2022: 8 · 2021: 12 · 2020: 13 · 2019: 9 · 2018: 13 · 2017: 17 · 2016: 17 · 2015: 19 · 2014: 14 · 2013: 22 · 2012: 20
FWCI
2.67
Type
journal article
Language
en
Open access
closed
Locations
  • CNS Drugs (publishedVersion)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
dopamine dysregulation syndrome, Parkinson's disease, dopamine replacement therapy, impulse control disorders, punding, gambling addiction, hypersexuality, compulsive buying, compulsive eating, trait impulsivity, D2-like receptors, decision-making, ventral striatum, levodopa, apomorphine, dopamine agonists, cognitive behavioral therapy, deep brain stimulation, addiction models
MeSH terms
Clinical Trials as Topic, Cognition, Dopamine, Humans, Iatrogenic Disease, Parkinson Disease, Reward, Risk Factors, Syndrome, Dopamine Agonists, Substance-Related Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review